Cerenics licenses new treatment of aortic valve stenosis
Cerenis Therapeutics, a pharmaceutical company developing HDL-related compounds for the treatment of cardiovascular and metabolic diseases, has licensed intellectual property supporting an HDL-therapy based investigational treatment of aortic valve stenosis (AVS).
The technology is based on the findings of a study, led by Jean-Claude Tardif, MD, at the Montreal Heart Institute Research Centre in Canada, which was published in the April 2008 British Journal of Pharmacology.
In Tardif’s placebo-controlled study of rabbit AVS models, the aortic valve opening in the treatment group returned to a near-normal state and aortic valve thickness had decreased after 14 days of treatment. In addition, the treatment group showed significantly less extensive valve lesions than the control group, as well as reduced aortic valve calcification.
The technology is based on the findings of a study, led by Jean-Claude Tardif, MD, at the Montreal Heart Institute Research Centre in Canada, which was published in the April 2008 British Journal of Pharmacology.
In Tardif’s placebo-controlled study of rabbit AVS models, the aortic valve opening in the treatment group returned to a near-normal state and aortic valve thickness had decreased after 14 days of treatment. In addition, the treatment group showed significantly less extensive valve lesions than the control group, as well as reduced aortic valve calcification.